For the third quarter of the fiscal year ending March 2026, net sales were \u00a592,456 million (3.6% increase YoY), operating income was \u00a54,609 million (47.9% increase YoY), and net income attributable to owners of the parent was \u00a54,119 million (68.9% increase YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4569-20260204-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending March 2026, net sales were \u00a592,456 million (3.6% increase YoY), operating income was \u00a54,609 million (47.9% increase YoY), and net income attributable to owners of the parent was \u00a54,119 million (68.9% increase YoY).","jir_summary":"### Overview of Business Performance\nFor the third quarter of the fiscal year ending March 2026, consolidated results were net sales of \u00a592,456 million (3.6% increase YoY), operating income of \u00a54,609 million (47.9% increase YoY), ordinary income of \u00a55,097 million (35.8% increase YoY), and net income attributable to owners of the parent of \u00a54,119 million (68.9% increase YoY). Growth in new drug sales and the recording of special gains from the sale of investment securities contributed to the increase in profits. Domestic sales of new pharmaceuticals were \u00a565,042 million (3.4% increase YoY), overseas new pharmaceuticals were \u00a5580 million (12.1% increase YoY), and generic drugs sales were \u00a526,833 million (3.7% increase YoY).\n\n### Overview of Financial Position and Future Outlook\nTotal assets stood at \u00a5194,266 million, net assets at \u00a5138,869 million, and equity ratio improved to 71.5% compared to the previous fiscal year-end. Research and development expenses were \u00a57,534 million (6.5% decrease YoY), with progress seen in key development pipelines. The full-year earnings forecast for the fiscal year ending March 2026 anticipates net sales of \u00a5127,000 million (2.4% decrease YoY), operating income of \u00a56,100 million (51.5% decrease YoY), and net income attributable to owners of the parent of \u00a54,800 million (47.2% decrease YoY), with no recent revisions to this guidance.","jir_financial_highlights":"Net Sales: \u00a592,456 million (3.6% increase YoY)\nOperating Income: \u00a54,609 million (47.9% increase YoY)\nOrdinary Income: \u00a55,097 million (35.8% increase YoY)\nNet Income Attributable to Owners of Parent: \u00a54,119 million (68.9% increase YoY)\nQuarterly Net Income per Share: \u00a571.71 (Unknown)\nTotal Assets: \u00a5194,266 million (Increase compared to the end of the previous consolidated fiscal year)\nNet Assets: \u00a5138,869 million (Increase compared to the end of the previous consolidated fiscal year)\nEquity Ratio: 71.5% (Up 1.1 points from the end of previous consolidated fiscal year)","jir_category":"","jir_hashtags":"#KyorinPharmaceutical, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a592,456 million (3.6% increase YoY)\nOperating Income: \u00a54,609 million (47.9% increase YoY)\nNet Income Attributable to Owners of Parent: \u00a54,119 million (68.9% increase YoY)","jir_meta_title":"Kyorin Pharmaceutical Q3 FY2026 Financial Summary: Net Sales \u00a592,456 million, Operating Income Up 47.9%","jir_meta_description":"Kyorin Pharmaceutical's Q3 FY2026 Financial Summary reports net sales of \u00a592,456 million (3.6% increase YoY), operating income of \u00a54,609 million (47.9% increase YoY), and net income attributable to owners of parent of \u00a54,119 million (68.9% increase YoY).","jir_og_title":"Kyorin Pharmaceutical Announces Q3 FY2026 Financial Summary","jir_og_description":"Kyorin Pharmaceutical's Q3 FY2026 Financial Summary reports strong performance with net sales of \u00a592,456 million, operating income of \u00a54,609 million, and net income of \u00a54,119 million.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-24001","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n